Company News - Hims shares increased in late trading [1] - Hims is in discussions with Novo Nordisk [1] - The discussion is about making Novo's new obesity pill available on Hims' site [1] Industry Focus - Telehealth company Hims is expanding its offerings [1] - The potential partnership focuses on obesity treatment [1]

Clinical Trial Results & FDA Approval - Lilly's oral pill data for obesity and Type 2 diabetes initially caused significant market disappointment [1][2] - The recent data is viewed as the final step before submitting plans to the FDA for approval of the pill [2] - FDA approval is anticipated no earlier than 2026 [4] Market Expectations & Potential - Long-term expectations for the pill have decreased due to weight loss percentage and gastrointestinal side effects [3] - Despite lowered expectations, the pill is still projected to become a multi-billion dollar product in the US market [3] Side Effects & Advantages - The pill's side effects include diarrhea, nausea, and gastrointestinal issues, comparable to other medications like Wegovy [5] - The primary advantage of the pill is its convenience as a once-daily oral medication compared to weekly injections [6]